What is the issue size of Mono Pharmacare IPO?

The issue size of the Mono Pharmacare IPO is Rs 14.84 cr.

What is 'pre-apply' for Mono Pharmacare IPO?

Pre-apply will alow you to apply for the Mono Pharmacare IPO 2 days before the subscription period starts.

If I pre-apply for Mono Pharmacare IPO, when will my order get placed?

Your order will be placed on the exchange as soon as the Mono Pharmacare IPO bidding starts. You will receive a UPI request within 24 hours after the bidding period opens.

When will I know if my Mono Pharmacare IPO order is placed?

We will notify you when your Mono Pharmacare IPO order is placed with the exchange.

What are the open and close dates of the for Mono Pharmacare IPO?

Mono Pharmacare IPO will be open between 28 August - 30 August, 2023.

What is the lot size and minimum order quantity of the Mono Pharmacare IPO?

Mono Pharmacare Limited IPO lot size is 4000 shares.

What are the allotment dates for the Mono Pharmacare IPO?

Mono Pharmacare IPO allotment date is 4 September, 2023. For Mono Pharmacare IPO allotment status check, you can visit the website of the registrar of the IPO.

Who is the registrar of Mono Pharmacare IPO?

Mono Pharmacare IPO registrar is Bigshare Services Pvt Ltd. You can check Mono Pharmacare IPO allotment status on the website of the registrar.

Where is the Mono Pharmacare IPO getting listed?

The shares are proposed to be listed on NSE SME.

Mono Pharmacare SME IPO

Mono Pharmacare Limited

₹1,04,000 /4000 sharesMinimum Investment

Mono Pharmacare SME IPO Listing DetailsListed OnIssue PriceListing PriceListing Gains
NSE₹28.00₹29.00₹1.00 (3.57%)
Mono Pharmacare SME IPO DetailsBidding DatesMin. InvestmentLot SizePrice Range
28 Aug ‘23 - 30 Aug ‘23₹1,04,0004,000₹26 - ₹28
Issue SizeIPO Doc
14.84CrRHP PDF
About Mono Pharmacare SMEMono Pharmacare, incorporated in 1994, operates in the pharmaceutical industry. It specializes in the marketing and distribution of pharmaceutical products. They collaborate with contract manufacturers to produce medications according to their formulations, which are then sold under the 'DLS Export' brand. In addition to this, they serve as distributors for various pharmaceutical companies.
Their product lineup includes various medicines, such as antibiotics, antifungal treatments, cold and allergy remedies, antacids, pain relievers, nutritional supplements, skin care products, antiseptics, cardiac medications, diabetic treatments, and cosmetics.
Currently, the company conducts its operations exclusively in the western region of Gujarat, with a primary focus on Ahmedabad city.
;
Parent Organisation
Mono Pharmacare Limited
Founded
1994
Managing Director
Mr. Panilam Lakhatariya
Strengths & Risks
The company has an extensive product lineup encompassing various categories, including antibiotics, antifungal medications, cough-cold & anti-allergic remedies, antacid and antiemetics, analgesics and antipyretics, nutraceuticals, skincare products, antiseptic solutions, cardiac medications, diabetic treatments, and cosmetics.
As of February 28, 2023, it collaborated with pharmaceutical distributors and stockists. Additionally, the company maintains relationships with 3,036 customers and vendors, comprising both retail pharmacy stores and wholesalers.
The company sources its formulations from plants with WHO, ISO, and GMP certifications. These certified suppliers ensure the production of the products by employing high-quality ingredients and advanced methods, following pharmaceutical industry regulations and standards.
Mono Pharmacare collaborates with 19 pharmaceutical companies/entities for contract manufacturing. These entities produce the company's goods based on its orders, typically taking 45 to 60 days as per the agreement.
The company heavily relies on its top ten customers to generate most of its revenue, contributing 72.07% of the revenue as of March 31, 2023. 
The company usually doesn't engage in long-term agreements with its customers. If it can't maintain these arrangements, it could significantly impact its business and financial condition.
The company is currently dealing with legal proceedings that, if decided unfavorably, could impact its business and financial situation.
As of March 31, 2023, the company has outstanding unsecured loans amounting to Rs. 1,584.45 lakhs, which the lenders can demand repayment of at any time.
As of March 31, 2023, the company had long-term borrowings of Rs. 1,532.46 lakhs and short-term borrowings of Rs. 2,460.24 lakhs. In the future, the company anticipates incurring additional debts to meet its business requirements.
Financials
*All values are in Rs. Cr
No Graph Data To Display
Application detailsApply asPrice bandApply upto
Regular₹26 - 28₹2 Lakh
High Networth Individual₹26 - 28₹2 - 5 Lakh
For Mono Pharmacare SME IPO, eligible investors can apply as Regular.

Listed On	Issue Price	Listing Price	Listing Gains
NSE	₹28.00	₹29.00	₹1.00 (3.57%)

Bidding Dates	Min. Investment	Lot Size	Price Range
28 Aug ‘23 - 30 Aug ‘23	₹1,04,000	4,000	₹26 - ₹28

Issue Size	IPO Doc
14.84Cr	RHP PDF

Apply as	Price band	Apply upto
Regular	₹26 - 28	₹2 Lakh
High Networth Individual	₹26 - 28	₹2 - 5 Lakh

Vaishnavi Tech Park, 3rd & 4th Floor
Sarjapur Main Road, Bellandur
Bengaluru – 560103
Contact Us
PRODUCTS
StocksFutures & OptionsIPOMutual FundsCreditBill Payments
GROWW
About UsPricingBlogMedia & PressCareersHelp and Support
QUICK LINKS
AMC Mutual FundsCalculatorsGlossaryOpen Demat AccountGroww DigestSitemap
ⓒ 2016-2023 Groww. All rights reserved, Built with ♥in India

ABOUT GROWW

Groww is India’s growing financial services platform where users can find their investment solutions pertaining to mutual funds, stocks, US Stocks, ETFs, IPO, and F&Os, to invest their money without hassles.

Groww objectively evaluates stocks and mutual funds and does not advise or recommend any stocks, mutual funds or portfolios. Investors shall invest at their own discretion, will and consent. Groww, at any time, does not guarantee fixed returns on the capital invested.

Groww helps investors -

· By providing 100% paperless online free Demat and trading account opening

· By providing an objective evaluation of products available on the platform

· By being transparent about fees and charges involved while investing in a product

· By offering decision-making assistance by providing technical analysis with advanced charts, well-designed line & candlestick charts that indicate share price movements, and market indices, along with more details about all registered and listed companies

SECURE TRANSACTIONS ON GROWW

All transactions on Groww are safe and secure. Users can invest through SIP or Lumpsum using Netbanking through all supported banks. It uses BSE Star MF (with Member code 11724) as transaction platform.

TRADE AND INVEST SECURELY WITH GROWW

Stocks, Mutual fund investments, F&Os, etc., are very popular with individual investors because of their numerous benefits. On Groww, an investor can -

- Invest in Nifty 50 (NSE) & Sensex (BSE) listed stocks

- Diversify across multiple stocks and other instruments

- Start SIP with any amount (as low as Rs. 500)

- Switch regular funds to direct funds

- Start automated monthly investments (SIP), and benefit from many more features

All type of mutual funds are available on Groww.

INVESTING IN MUTUAL FUND PORTFOLIOS

Portfolio is collection of mutual funds designed to meet your investment goals. Investing in mutual fund portfolios helps you in diversifying your investments and reduces the risk. Portfolios also help you in assigning an investment goals and make it easy for you to save for and achieve your goals. You can create a portfolio yourself or ask an expert to build it for you.

ATTENTION INVESTORS

1. For Stock Broking Transaction 'Prevent unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day...Issued in the interest of Investors.

2. For Depository Transaction 'Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL/NSDL on the same day...Issued in the interest of investors.

3. KYC is a one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

4. If you are subscribing to an IPO, there is no need to issue a cheque. Please write the Bank account number and sign the IPO application form to authorize your bank to make payment in case of allotment. In case of non allotment the funds will remain in your bank account.

· Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website.

· Awareness regarding guidelines on Margin collection

1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

3. Pay 20% upfront margin of the transaction value to trade in cash market segment.

4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.

Issued in the interest of Investors

DISCLAIMER

NextBillion Technology Private Limited (CIN: U65100KA2016PTC092879) is a member of NSE & BSE with SEBI Registration no: INZ000301838, Depository Participant of CDSL Depository with SEBI Registration no: IN-DP-417-2019 and Mutual Fund distributor with AMFI Registration No: ARN-111686. Registered office and Correspondence office - No.11, 2nd floor, 80 FT Road, 4th Block, S.T Bed, Koramangala, Bengaluru – 560034. For any grievances related to Stock Broking/DP, please write to [email protected] , please ensure you carefully read the Risk Disclosure Document as prescribed by SEBI.

Procedure to file a complaint on SEBI SCORES: Register on the SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.

NextBillion Technology Private Limited makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Unless otherwise specified, all returns, expense ratio, NAV, etc are historical and for illustrative purposes only. Future will vary greatly and depends on personal and market circumstances. The information provided by our blog is educational only and is not investment or tax advice.

Mutual fund investments are subject to market risks. Please read all scheme related documents carefully before investing. Past performance of the schemes is neither an indicator nor a guarantee of future performance.

Terms and conditions of the website/app are applicable. Privacy policy of the website is applicable.